This conference will review the latest medications and therapies in liver treatment and transplantation. The results of trials and real-world data using oral drugs to treat chronic viral hepatitis B and C, non-alcoholic fatty liver diseases, primary biliary cirrhosis, primary sclerosing cholangitis, hepatocellular carcinoma and complications of end-stage liver disease including thrombocytopenia will be reviewed in detail. New Treatments in Chronic Liver Disease is a comprehensive yet concise program for updating physicians on these and other commonly encountered problems in the treatment of liver diseases.

EDUCATIONAL OBJECTIVES

After attending this live activity, participants should be able to:

• Assess AASLD guidelines on viral hepatitis, autoimmune hepatitis and reproductive health, and chronic liver disease.
• Review vascular disorders and coagulation management principles for patients with chronic liver disease.
• Summarize guidelines on NAFLD (AGA), DILI and hemochromatosis (ACG) and non-invasive markers of fibrosis (EASL).
• Evaluate drugs in development for PBC and PSC.
• Employ strategies for treating and managing ascites and hepatorenal syndrome.
• Describe advances in HCC therapy and management of acute-on-chronic liver disease.

ACCREDITATION

Scripps Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Scripps Health designates this live activity for a maximum of 10 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

For more information please visit the official event page.